BRAF and colorectal carcinoma: Furthermore, almost all recurrent and advanced CRC patients are routinely screened for KRAS/BRAF genotype at the initiation of the first line chemotherapy in our institution since the use of cetuximab was approved for the treatment of CRC patients in Japan.